<DOC>
	<DOCNO>NCT01247961</DOCNO>
	<brief_summary>This pilot trial evaluate follow patient acute pancreatitis : 1 . Safety profile early treatment intravenous dexamethasone 2 . Impact dexamethasone systemic inflammation patient acute pancreatitis 3 . Provide preliminary data potential impact early treatment steroid clinical outcome</brief_summary>
	<brief_title>Early Treatment With Dexamethasone Mild Acute Pancreatitis</brief_title>
	<detailed_description />
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Age &gt; =18 year Diagnosis acute pancreatitis confirm least 2 follow : 1 . Typical epigastric abdominal pain 2 . Elevation amylase/lipase &gt; 3 time upper limit normal and/or 3 . Confirmatory finding crosssectional imaging Enrollment within 8 hour presentation Class II great NYHA heart failure Oxygen dependent COPD Chronic kidney disease &gt; stage 2 Cirrhosis Existing necrosis abdominal CT Organ dysfunction prior enrollment Sepsis Acute respiratory distress syndrome Malignancy remission least 5 year Active drug use Known allergy dexamethasone Altered mental status Insulinrequiring diabetes Abdominal surgery within 60 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>